Vaxart, Inc. splits its revenue into 6 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Government Contract at $224.5 million, 95% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Jun 30, 2017
|
FY 2016
Jun 30, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
181
|
237
|
29
|
7
|
0
|
1
|
4
|
10
|
4
|
9
|
9
|
| Government Contract |
—
|
225
+803.2%
share 94.6%
|
25
share 86.6%
|
—
|
—
|
—
|
—
|
-0
share -0.2%
|
—
|
—
|
—
|
| License |
—
|
9
share 3.7%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Royalty |
—
|
—
|
—
|
—
|
—
|
—
|
3
-33.4%
share 73.2%
|
4
share 45.1%
|
—
|
—
|
—
|
| Non Cash Royalty Revenue |
—
|
2
-49.8%
share 0.8%
|
4
-2.0%
share 13.4%
|
4
+3563.6%
share 53.1%
|
0
-87.8%
share 100.0%
|
1
-0.8%
share 98.5%
|
1
share 21.9%
|
—
|
—
|
—
|
—
|
| Customer Service Contracts |
—
|
—
|
—
|
—
|
—
|
0
-93.4%
share 1.5%
|
0
-51.2%
share 4.9%
|
0
share 4.1%
|
—
|
—
|
—
|
| Grant |
—
|
—
|
0
-100.0%
share 0.0%
|
3
share 46.9%
|
0
share 0.0%
|
—
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VXRT (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Accelerated filer, Smaller reporting company
- SEC CIK
- 72444
- Former names
- Aviragen Therapeutics, Inc. (until Feb 15, 2018); Biota Pharmaceuticals, Inc. (until Apr 13, 2016); NABI BIOPHARMACEUTICALS (until Nov 8, 2012); NABI BIOPHARMACEUTICALS (until Jun 29, 2010); NABI /DE/ (until Feb 14, 2002)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.